检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:鲁霞 Lu xia(Department ofgastroenterology,west chengdu hospital,Chengdu, Sichan 610000, China)
机构地区:[1]成都市西区医院消化内科,四川成都3610000
出 处:《医药前沿》2019年第11期108-109,共2页Journal of Frontiers of Medicine
摘 要:目的:比较雷贝拉唑与奥美拉唑两种质子泵抑制剂联合克拉霉素、羟氨苄青霉素治疗HP阳性胃溃疡的疗效。方法:选取我院2017年11月-2018年11月间收治的90例HP阳性胃溃疡患者,随机分为A组和B组,各45例。A组给予雷贝拉唑联合克拉霉素、羟氨苄青霉素治疗,B组给予奥美拉唑联合克拉霉素、羟氨苄青霉素治疗。比较两组HP转阴率及临床疗效情况。结果:A组治疗后HP转阴率为86.67%,B组转阴率为66.67%,A组治疗后HP转阴率显著高于B组(x^2=5.031,P<0.05);A组总有效率为95.56%,B组总有效率80.00%,A组总有效率显著高于B组(x^2=5.075,P<0.05)。结论:奥美拉唑及雷贝拉唑联合抗生素对HP阳性胃溃疡的疗效均较满意,相较而言,雷贝拉唑对HP阳性胃溃疡患者HP的转阴率及临床疗效更好。Objective To compare the efficacy of Rabeprazole and Omeprazole proton pump inhibitors combined with Clarithromycin and Ampicillin in the treatment of HP-positive gastric ulcer Methods 90 patients with Hp-positive gastric ulcer admitted to our hospital from November 2017 to November 2018 were randomly divided into group A and group B,45 cases in each group. Group A was treated with rabeprazole combined with clarithromycin and ampicillin,while group B was treated with omeprazole combined with clarithromycin and ampicillin. The negative rate of Hp and the clinical effect of the two groups were compared. Results After treatment,the negative conversion rate of Hp was 86.67% in group A and 66.67% in group B. The negative conversion rate of Hp in group A was significantly higher than that in group A (P<0.05);the total effective rate was 95.56% in group A,80.00% in group B,and the total effective rate in group A was significantly higher (P<0.05). Conclusion The efficacy of omeprazole and rabeprazole combined with antibiotics in treating HP-positive gastric ulcer is satisfactory. Compared with rabeprazole,the negative conversion rate and clinical efficacy of rabeprazole for HP-positive gastric ulcer patients are better。
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.74